

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09854356
Filing Date	2001-05-09
First Named Inventor	Cheever et al.
Art Unit	1643
Examiner Name	Lynn Bristol
Attorney Docket Number	CRX113US1

U.S. PATENTS[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
LAB	1	5801005		1998-09-01	Cheever	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)**U.S. PATENT APPLICATION PUBLICATIONS**[Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)**FOREIGN PATENT DOCUMENTS**[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)**NON-PATENT LITERATURE DOCUMENTS**[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

/Lynn Bristol/

08/28/2007

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09854356
Filing Date	2001-05-09
First Named Inventor	Cheever et al.
Art Unit	1643
Examiner Name	Lynn Bristol
Attorney Docket Number	CRX113US1

LAB	1	CHAMBERLAIN AND KAUFMAN; Innovations and strategies for the development of anticancer vaccines; Expert Opinion on Pharmacotherapy; 2000; 1/4; 603-614;	<input type="checkbox"/>
	2	DISIS AND GRABSTEIN; Generationn of Immunity to the HER-2/neu Oncogenic Protein in Patients with Breast and Ovarian Cancer Using a Peptide-based Vaccine; Clinical Cancer Research; June 1999; 5; 1289-1297;	<input type="checkbox"/>
	3	DISIS AND CHEEVER; HER-2/new Protein: A Target for Antigen-specific Immunotherapy of Human Cancer; Advances in Cancer Research; 1997; 71; 343-371;	<input type="checkbox"/>
	4	EZZEL ET AL.; Cancer Vaccines - An Idea Whose Time has Come?; J. NIH Research; 1995; 7; 46-49;	<input type="checkbox"/>
	5	KUREBAYASHI; Biological and Clinical Significance of HER2 Overexpression in Breast Cancer; Breast Cancer; Jan 2001; 8/1; 45;	<input type="checkbox"/>
	6	LIMENTANI ET AL.; A recombinant HER2 protein evaluated for cancer immunotherapy: induction of specific antibodies and T-cells; (Poster) 18th EORTC-NCI-AACR Symposium, Prague, CZ; 7-11 Nov 2006;	<input type="checkbox"/>
	7	LIMENTANI ET AL.; Evaluation of a recombinant HER2 vaccine: Induction of specific antibodies, T-cells and preliminary activity in metastitic breast cancer patients; J. Clinical Oncology (Abstract, 2006 ASCO Annual Meeting); 20 Jun 2006; 631;	<input type="checkbox"/>
	8	MURRAY ET AL.; Clinical Trials of Her2/neu specific vaccines.; Seminars in Oncology; Dec 2000; 27/6 Supp 11; 71-75;	<input type="checkbox"/>
	9	ROSS AND FLETCHER; The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy; The Oncologist; 1998; 3; 237-252;	<input type="checkbox"/>
	10	SIKIC; New approaches in cancer treatment; Annals of Oncology; 1999; 10(Suppl 6); S149-S153;	<input type="checkbox"/>
	11	ZAKS AND ROSENBERG; Immunization with a Peptide Epitope (p369-377) from HER-2/neu Leads to Peptide-specific Cytotoxic T Lymphocytes That Fail to Recognize HER-2/neu+ Tumors; Cancer Research; 1 Nov 1998; 58; 4902-4908;	<input type="checkbox"/>